Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do

Executive Summary

FDA's three-month postponement of a decision on AstraZeneca PLC’s NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.

You may also be interested in...

AstraZeneca's Brilique Approved In The EU

AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.

GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix

Study results don't prove clinical benefit for point-of-care testing, but trial may not have been sufficiently powered to show a difference.

AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon

Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts